Amneal Pharmaceuticals (NASDAQ:AMRX) EVP Sells $2,619,308.72 in Stock

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) EVP Andrew Boyer sold 279,244 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $9.38, for a total value of $2,619,308.72. Following the completion of the sale, the executive vice president owned 152,426 shares in the company, valued at approximately $1,429,755.88. This trade represents a 64.69% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Amneal Pharmaceuticals Stock Performance

NASDAQ:AMRX opened at $9.59 on Friday. Amneal Pharmaceuticals, Inc. has a 1 year low of $6.68 and a 1 year high of $9.79. The stock has a fifty day moving average price of $8.38 and a two-hundred day moving average price of $8.01. The stock has a market capitalization of $3.01 billion, a price-to-earnings ratio of 959.96 and a beta of 1.11.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its earnings results on Tuesday, August 5th. The company reported $0.23 EPS for the quarter, topping the consensus estimate of $0.17 by $0.06. Amneal Pharmaceuticals had a net margin of 0.12% and a negative return on equity of 189.49%. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.700-0.750 EPS. On average, analysts predict that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current year.

Institutional Trading of Amneal Pharmaceuticals

Several large investors have recently modified their holdings of AMRX. Nuveen LLC purchased a new stake in Amneal Pharmaceuticals in the 1st quarter valued at approximately $19,581,000. Nantahala Capital Management LLC lifted its position in shares of Amneal Pharmaceuticals by 37.3% in the fourth quarter. Nantahala Capital Management LLC now owns 3,665,529 shares of the company’s stock valued at $29,031,000 after acquiring an additional 995,586 shares in the last quarter. Rubric Capital Management LP boosted its stake in shares of Amneal Pharmaceuticals by 9.1% during the second quarter. Rubric Capital Management LP now owns 11,710,332 shares of the company’s stock valued at $94,737,000 after acquiring an additional 974,355 shares during the last quarter. Woodline Partners LP increased its position in Amneal Pharmaceuticals by 165.2% during the 1st quarter. Woodline Partners LP now owns 1,504,095 shares of the company’s stock worth $12,604,000 after purchasing an additional 937,035 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in Amneal Pharmaceuticals by 6.2% in the 1st quarter. Vanguard Group Inc. now owns 15,762,727 shares of the company’s stock valued at $132,092,000 after purchasing an additional 920,758 shares during the last quarter. 31.82% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on AMRX. The Goldman Sachs Group began coverage on shares of Amneal Pharmaceuticals in a report on Friday, June 6th. They issued a “buy” rating and a $12.00 target price for the company. Wall Street Zen cut Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, May 13th. Five equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $11.60.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.